Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
Year: 2024
Type: conference-abstract
Source: Blood
Institutions: University College London, Memorial Sloan Kettering Cancer Center, Methodist Healthcare, University of California, San Francisco, City Of Hope National Medical Center, University of California, Davis, Moffitt Cancer Center, University of Chicago, Dana-Farber Cancer Institute, Autolus (United Kingdom), The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039470